Pioneering Efforts Produce Regenerative Products

Diabetic patients suffering diabetic foot ulcers (wounds) are benefiting from pioneering efforts in wound therapy. Tissue Regenix, an international medical technology company is leading the development of a range of regenerative products to make specialized replacement tissue using biological (human & animal) materials.
The company offers an expanding roster of products based on their patented dCELL® decellularization technology to provide acellular tissue scaffolds which are not rejected by the patient’s body. DermaPure® is a new decellularized human dermis product from Tissue Regenix used by physicians to help promote wound healing. Initial clinical use has demonstrated that DermaPure® allografts may have scaffold characteristics – including elasticity, porosity and bio-compatibility – comparable to natural tissue, which have been shown to promote beneficial cellular activity during healing.